08 February 2021 : Clinical Research
Diagnosis of Prostate Cancer in Patients with Prostate-Specific Antigen (PSA) in the Gray Area: Construction of 2 Predictive Models
Ming Chen1BCE, Ting Ma1CDE, Jun Li1AEG*, Hai-Jun Zhang2D, Qiang Li3F, Jia-Jia Wang1F, Tian Sang1B, Chun-Li Cao1D, Xin-Wu Cui4AEFDOI: 10.12659/MSM.929913
Med Sci Monit 2021; 27:e929913
Table 4 Verifying the diagnostic value of clinical parameters by using univariate and multivariate logistic regression analyses in predicting NCS-PCa and CS-PCa.
| Parameters | Univariable analysis | Multivariable analysis | |||||
|---|---|---|---|---|---|---|---|
| OR (95% CI) | Standard error | P | Coefficient | Standard error | OR (95% CI) | P | |
| Constant | – | – | – | 5.73 | 1.97 | – | <0.01 |
| Age | 1.00 (0.94, 1.06) | 0.03 | 0.89 | – | – | – | – |
| tPSA | 1.14 (0.82, 1.58) | 0.13 | 0.43 | – | – | – | – |
| f/t PSA | 0.25 (0.01, 1.72) | 4.05 | 0.59 | – | – | – | – |
| PSADa | 66.46 (6.93, 637.02) | 1.15 | <0.01 | 4.45 | 1.28 | 85.73 (6.95, 1058.08) | <0.01 |
| DRE | 2.28 (0.47, 11.05) | 0.81 | 0.31 | – | – | – | – |
| TRUS (1)b | 1.34 (0.46, 3.89) | 0.54 | 0.59 | – | – | – | – |
| TRUS (2)c | 1.43 (0.39, 5.26) | 0.67 | 0.60 | – | – | – | – |
| mpMRI (1)d | 4.40 (1.11, 17.48) | 0.70 | 0.03 | 2.10 | 0.95 | 8.17 (1.27, 52.71) | 0.02 |
| mpMRI (2)e | 4.71 (1.40, 15.87) | 0.62 | 0.01 | 1.35 | 0.73 | 3.84 (0.91, 16.17) | 0.04 |
| PCa – prostate cancer; NCS-PCa – nonclinically significant prostate cancer; CS-PCa – clinically significant prostate cancer; OR – odds ratio; CI – confidence interval; PSA – prostate-specific antigen; tPSA – total PSA; f/t PSA – free/total PSA; PSAD – PSA density; DRE – digital rectal examination; TRUS – transrectal ultrasound; mpMRI – multiparametric magnetic resonance imaging. ‘−’ – Not applicable. a This parameter has been log-transformed; b Negative vs Equivocal in TRUS; c Equivocal vs Suspicious in TRUS; d Negative vs Equivocal in mpMRI; e Equivocal vs Suspicious in mpMRI. | |||||||